Neurology & Neurotherapeutics - NE Outside Agreements

Medicine & Life Sciences

1. Multiple Sclerosis 100%
2. Tuberous Sclerosis 36%
3. Natalizumab 29%
4. Holoprosencephaly 28%
5. Therapeutics 24%
6. Central Nervous System 19%
7. Cerebral Palsy 19%
8. Neuromyelitis Optica 18%
9. T-Lymphocytes 17%
10. Central Nervous System Diseases 16%
11. Autoimmune Diseases of the Nervous System 16%
12. Child 16%
13. Relapsing-Remitting Multiple Sclerosis 16%
14. Autoimmune Experimental Encephalomyelitis 15%
15. Glioblastoma 15%
16. Glatiramer Acetate 14%
17. Chronic Progressive Multiple Sclerosis 13%
18. B-Lymphocytes 13%
19. abobotulinumtoxinA 12%
20. Hydroxymethylglutaryl-CoA Reductase Inhibitors 12%
21. ErbB Receptors 11%
22. Epilepsy 11%
23. Brain 10%
24. epidermal growth factor receptor VIII 10%
25. Astrocytoma 10%
26. Carbamazepine 10%
27. Autoimmunity 9%
28. Mutation 9%
29. Safety 9%
30. Cerebrospinal Fluid 9%
31. Everolimus 8%
32. siponimod 8%
33. Glioma 8%
34. Pharmaceutical Preparations 8%
35. Neoplasms 8%
36. Progressive Multifocal Leukoencephalopathy 8%
37. Phenotype 8%
38. Angiomyolipoma 8%
39. Genes 7%
40. Interferon-beta 7%
41. Placebos 7%
42. Seizures 7%
43. Clinical Trials 7%
44. quinpramine 7%
45. Type A Botulinum Toxins 6%
46. Fingolimod Hydrochloride 6%
47. Somatosensory Evoked Potentials 6%
48. Demyelinating Diseases 6%
49. Immunosuppressive Agents 6%
50. Rituximab 6%
51. Acute Disseminated Encephalomyelitis 6%
52. Incidence 6%
53. Interferons 6%
54. Alemtuzumab 6%
55. Mitoxantrone 5%
56. N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide 5%
57. Receptor-Interacting Protein Serine-Threonine Kinases 5%
58. Pediatrics 5%
59. teriflunomide 5%
60. Aquaporin 4 5%
61. Neuroimaging 5%
62. Oligodendrocyte-Myelin Glycoprotein 5%
63. Injections 5%
64. 4-dichlorobenzene 5%
65. Recurrence 5%
66. Monoclonal Antibodies 5%
67. Biomarkers 5%
68. Systematic Reviews 5%
69. Cladribine 5%
70. Autoimmune Diseases 5%
71. MHC class II transactivator protein 5%